查詢結果分析
相關文獻
- Tissue Polypeptide Antigen, Carcinoembryonic Antigen, Carbohydrate Antigen, and CA125 Levels as Tumor Markers in Squamous Cell Carcinoma of the Head and Neck
- 腫瘤標幟(CA19-9 & SCC)之簡介
- Squamous Cell Carcinoma of the Bladder: A Ten-Year Retrospective Study
- 增生性疣性白斑--初期研究
- 慢性腎衰竭並存泌尿道上皮細胞癌--一病例報告
- 肺鱗狀上皮細胞癌皮膚轉移:病例報告及文獻回顧
- 慢性骨髓炎併發鱗狀上皮細胞癌--病例報告及文獻回顧
- 侵犯性上泌尿道移形上皮細胞癌之治療
- Definitive Radiotherapy with Or Without Chemotherapy for Resectable Head and Neck Cancer
- 陰莖偽上皮細胞增生角化併雲母狀龜頭炎:一個病例報告並文獻回顧
頁籤選單縮合
題名 | Tissue Polypeptide Antigen, Carcinoembryonic Antigen, Carbohydrate Antigen, and CA125 Levels as Tumor Markers in Squamous Cell Carcinoma of the Head and Neck=頭頸部腫瘤之扁平上皮細胞癌以TPA, CEA, CA19-9及CA125做為腫瘤標幟之表現 |
---|---|
作者 | 郭文烈; 李家和; 何坤瑤; 蔡世盟; 江豐裕; 阮愷輝; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷期 | 15:3 1999.03[民88.03] |
頁次 | 頁152-158 |
分類號 | 416.8 |
關鍵詞 | 頭頸部腫瘤; 上皮細胞癌; 腫瘤標幟; Tumor marker; Squamous cell carcinoma; Head and neck cancer; |
語文 | 英文(English) |
中文摘要 | 98名未接受過治療的頭頸部上皮癌病人,其中包含喉癌 36 名, 口腔癌 48 名,鼻癌 14 名,以 TPA,CEA,CA19-9 及 CA 125 做為腫瘤標幟來檢測其治療前後之表現。另外 50 名健康個人及 42 名患耳鼻喉良性病灶之病人,被當做正常及疾病的控制組。喉癌病人中,TPA,CEA,CA19-9 及 CA125 之陽性率分別為 22.3%,27.8%,5.6%,及 0%。喉癌晚期病人的 TPA 值比早期者呈有意義的增高;相反地,CEA 值在早期病人則較高。口腔癌病人中,其陽性率分別為 TPA (25.0%),CEA(18.8%),CA 19.9(14.6%)及 CA 125(4.2%);而且,其腫瘤標幟值與口腔癌分期並無相關。腫瘤標幟對於鼻癌則以乎一點都無用處。以喉癌及口腔癌合併討論,則腫塊與淋巴腺大小和各種的腫瘤標幟值並無相關。僅有喉癌及口腔癌,其 TPA 值在治療前有上升者,其治療後呈有意義下降。總而言之,僅有 TPA 人 CEA 標幟在頭頸部癌症中,有某種程度的意義。 |
英文摘要 | Ninety-eight untreated patients with squamous cell carcinoma of the head and neck of different localizations (larynx 36, oral cavity 48, nasal cavity 14) were selected for a study to measure TPA, CEA, CA 19-9, CA125 pre-and post-therapy. Fifty healthy individuals and 42 patients with benign lesions were as normal and disease controls. The positive rates were 22.3%, 27.8%, 5.6% and 0% respectively in TPA, CEA, CA19.9 and CA125 markers in laryngeal cancer patients. The positive rates of TPA level was higher with significant difference in advanced stage group than in early stage group; conversely, the positive rate of CEA levels were somewhat high in early stages of laryngeal cancer. Meanwhile, the positive rates were 25.0%, 18.8%, 14.6% and 4.2% individually in the same order in oral cancer patients. There was no relationship between the marker levels and progression of the oral cancer. The tumor markers were almost of no use in detecting nasal cancer. It also seemed there was no relationship between the various serum levels and the tumor or nodal burden in laryngeal and oral cancer. Only TPA level decreased significantly after therapy in patients with laryngeal and oral cancer who had originally elevated marker levels. Conclusively, only TPA and CEA markers are of some clinical use in the disease. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。